Pentosan polysulfate sodium is the only oral medication that has been developed for bladder pain syndrome. As well as relieving pain and urgency, it is also thought to help to repair the bladder lining. The drug is taken as oral capsules three times a day. If this medicine is launched in the UK, it will offer an additional treatment option for patients with painful bladder syndrome.
Lumasiran, which is administered as a subcutaneous injection, is designed to reduce the levels of an enzyme called glycolate oxidase produced by the liver. Oxalate production is therefore inhibited. By reducing oxalate production, lumasiran has the potential to prevent the actual disease process that develops in PH1. If licensed, lumasiran may provide the first pharmacological treatment option for patients with PH1 who do not have any approved treatment.